Healthcare [ 4/11 ] | Biotechnology [ 50/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 23 | 0.44 Increased by +129.73% | 0.66 Decreased by -33.33% |
| May 24, 23 | -0.54 Increased by +74.04% | -0.58 Increased by +6.90% |
| May 11, 23 | -0.54 Increased by +84.57% | -0.68 Increased by +20.59% |
| Mar 29, 23 | 1.53 Increased by +143.71% | -0.75 Increased by +304.00% |
| Nov 14, 22 | -1.48 Increased by +63.00% | -1.75 Increased by +15.43% |
| Aug 11, 22 | -2.08 Increased by +48.00% | -1.87 Decreased by -11.23% |
| May 13, 22 | -3.50 Increased by +12.50% | -2.37 Decreased by -47.68% |
| Mar 31, 22 | -3.50 Increased by +17.65% | -3.75 Increased by +6.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 3.50 M Increased by +250.00% | -16.65 M Decreased by -133.84% | Decreased by -475.83% Increased by +33.19% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -6.28 M Increased by +70.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 68.00 K Decreased by -97.73% | 6.42 M Increased by +113.72% | Increased by +9.43 K% Increased by +705.38% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -9.59 M Decreased by -36.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 1.00 M Increased by +N/A% | -7.12 M Increased by +53.17% | Decreased by -712.20% Decreased by N/A% |
| Mar 31, 22 | 346.00 K Increased by +N/A% | -20.99 M Decreased by -31.18% | Decreased by -6.07 K% Decreased by N/A% |
| Dec 31, 21 | 3.00 M Increased by 0.00% | -46.75 M Decreased by -195.36% | Decreased by -1.56 K% Decreased by -195.36% |
| Sep 30, 21 | 0.00 Decreased by -100.00% | -7.04 M Increased by +2.67% | Decreased by N/A% Decreased by N/A% |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.